top of page
AdobeStock_dna2_edited.jpg

Technology

Clinical Domains

Oncology

- Prostate Cancer

- Brain Tumors

- Breast Cancer

- Cervical Cancer

- Ovarian Cancer

Neurology

- Alzheimer's 

- Dementia

- Multiple Sclerosis

- Epilepsy

- Parkinson's 

Psychiatry

- Depression

- Bipolar Disorder

- Schizophrenia

- ADHD

- Comorbidities

Harness the full potential of radiation boost therapy for prostate cancer treatment using RSIrs

 

 

SOLUTIONS - ONCOLOGY

Bringing precision to prostate cancer interventions 

​

It is very difficult to perfectly identify and contour suspected and clinically significant prostate cancer even when using MRI, which leads to sub-optimal interventions.

​

PHai-Pro combines AI with a quantitative diffusion MRI biomarker, restriction spectrum imaging score (RSIrs) which helps specialists distinguish clinically significant prostate cancer from healthy tissue.

 

PHai-Pro advances AI-enabled precision prostate cancer detection, enabling for radiologists, surgeons, and radiation oncologists to accurately contour tumors and maximize the potential of focal radiation, shown to improving treatment outcomes without increasing toxicity in a recent phase III randomized control trial.

 

Changing the way primary care physicians prescribe and treat mental health.

AdobeStock_dna2_edited_edited.jpg

 

 

SOLUTIONS - PSYCHIATRY  - asdlfkja

A step forward for Precision Psychiatry 

 

The PHai-MH physician's portal provides rapid insights to inform which pharmaceutical interventions for mental health disorders are right for each person. Instead of trial and error to determine the most effective medication, write prescriptions with precision - minimize side effects and improve health outcomes in a shorter time.  

​

In addition to pharmacogenomics, PHai-MH provides evidence-based polygenic risk scores to determine risk and onset for disease.  See our EU-funded REALMENT project for more information.

​

​

bottom of page